M
Mainz Biomed BV D
D
MYNZ
0.20930
USD
0.01
(3.61%)
Market Closed
Volume
102,284
EPS
-1
Div Yield
-
P/E
-0
Market Cap
13,403,781
Novo Nordisk Surges in Profit and Sales
6 months ago
Stocks news More
Title: Mainz Biomed NV
Sector: Healthcare
Industry: Diagnostics & Research
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.